CD274 and non-small cell lung carcinoma: Cemiplimab stands out as the second PD-(L)1 inhibitor that has demonstrated efficacy in advanced NSCLC, either on its own or in combination with chemotherapy, regardless of whether the cancer is of squamous or nonsquamous histology [12].